AstraZeneca Takes First Step For Lynparza/Imfinzi Combo In Ovarian Cancer

First PARP plus PD1/L1-inhibitor Combo Data

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.